Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide

Vera Adema; Laura Palomo; Andrea Toma; Olivier Kosmider; Francisco Fuster-Tormo; Rocío Benito; Rocío Salgado; Esperanza Such; María José Larrayoz; Blanca Xicoy; Jesus Maria Hernandez-Sanchez; Paolo Maietta; Alexander Neef; Michaela Fontenay; Mariam Ibañez; Maria Diez-Campelo; Sara Alvarez; Jaroslaw P Maciejewski; Pierre Fenaux; Francesc Sole

doi:10.1111/bjh.16558

Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide

Br J Haematol. 2020 May;189(4):e133-e137. doi: 10.1111/bjh.16558. Epub 2020 Mar 9.

Authors

Vera Adema^{1

2}, Laura Palomo¹, Andrea Toma³, Olivier Kosmider⁴, Francisco Fuster-Tormo¹, Rocío Benito^{5

6

7}, Rocío Salgado⁸, Esperanza Such^{9

10

11

12}, María José Larrayoz¹³, Blanca Xicoy¹⁴, Jesus Maria Hernandez-Sanchez^{5

6

7}, Paolo Maietta¹⁵, Alexander Neef^{9

10

11

12}, Michaela Fontenay⁴, Mariam Ibañez^{9

10

11

12}, Maria Diez-Campelo^{5

6

7}, Sara Alvarez¹⁵, Jaroslaw P Maciejewski², Pierre Fenaux⁴, Francesc Sole¹

Affiliations

¹ MDS Research Group, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.
² Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
³ Assistance Publique - Hôpitaux de Paris, Service Hematologie Clinique, Hôpital Universitaire Henri Mondor, Creteil, France.
⁴ Assistance Publique-Hopitaux de Paris, Service d'Hematologie Biologique, Hopitaux Universitaires Paris Centre, Paris, France.
⁵ Unidad de Diagnóstico Molecular y Celular del Cáncer, IBSAL, IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.
⁶ Department of Medicine, Universidad de Salamanca, Salamanca, Spain.
⁷ Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain.
⁸ Laboratorio de Citogenetica, Servicio de Hematología, Hospital Universitario fundación Jimenez Díaz, Madrid, Spain.
⁹ Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
¹⁰ Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.
¹¹ Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
¹² Centro de Investigación Biomédica en Red de Cáncer, Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
¹³ Department of Genetics, School of Medicine, University of Navarra, IDISNA, Pamplona, Spain.
¹⁴ Hematology Service, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain.
¹⁵ Scientific & Innovation Department, Nimgenetics, Madrid, Spain.

No abstract available

Keywords: Myelodysplastic syndromes; del(5q); lenalidomide; mutations; non-del(5q).

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lenalidomide / pharmacology
Lenalidomide / therapeutic use*
Mutation
Myelodysplastic Syndromes / drug therapy*

Substances

Lenalidomide

Publication types

MeSH terms

Substances

Grants and funding